Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xofluza, Opdivo, Keytruda, Bavencio under PMDA Risk Review
May 13, 2019
- Pituitary Dysfunction Added to Significant Adverse Reaction for Opdivo: MHLW
May 10, 2019
- MHLW Launches Survey on Authorized Generics to Get Data for Chuikyo Debate
May 8, 2019
- Next Public-Private Confab Set for May 20 before Full-Swing Pricing Debate
May 8, 2019
- Entyvio’s Crohn’s Disease Indication in Line for Approval in May
May 7, 2019
- Chuikyo Agrees to Require Genetic Info Submission for Insurance Coverage of Cancer Genomic Panel Tests
April 25, 2019
- PMDA to Set Up New Consultation Services for RWD Use in Regulatory Submissions
April 24, 2019
- MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
- Lilly’s EGFR Antagonist, Japan’s 1st Avastin Biosimilar Now in Line for June Approval
April 22, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- Japan Drug Production Up 1.5% to 6.7 Trillion Yen in 2017: MHLW Survey
April 18, 2019
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
- Entyvio’s Crohn’s Disease Use on Agenda for April 26 MHLW Panel Meeting
April 15, 2019
- CEFP Kicks Off Discussions towards 2020 Reimbursement Policy Reform
April 11, 2019
- Dupixent to Join Self-Injectable Drug List
April 11, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- MHLW Informally Notifies Drug Makers of Post-Oct. 1 NHI Prices
April 9, 2019
- Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
- Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
April 8, 2019
- Epadel OTC to Be Reclassified as “Class 1” Category under Stricter Rules on Sales: MHLW Panel
April 5, 2019
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…